MYELOID NEOPLASIA Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

Acute myeloid leukemia (AML) is the most common acute leukemia in adults and the second most common frequent leukemia of childhood. Patients may present with lymphopenia or pancytopenia at diagnosis. We investigated the mechanisms by which AML causes pancytopenia and suppresses patients' immune response. This study identified for the first time that AML blasts alter the immune microenvironment through enhanced arginine metabolism. Arginase II is expressed and released from AML blasts and is present at high concentrations in the plasma of patients with AML, resulting in suppression of T-cell proliferation. We extended these results by demonstrating an arginase-dependent ability of AML blasts to polarize surrounding monocytes into a suppressive M2-like phenotype in vitro and in engrafted nonobese diabetic-severe combined immunodeficiency mice. In addition, AML blasts can suppress the proliferation and differentiation of murine granulocyte-monocyte progenitors and human CD34(+) progenitors. Finally, the study showed that the immunosuppressive activity of AML blasts can be modulated through small-molecule inhibitors of arginase and inducible nitric oxide synthase, suggesting a novel therapeutic target in AML. The results strongly support the hypothesis that AML creates an immunosuppressive microenvironment that contributes to the pancytopenia observed at diagnosis.

[1]  V. Cerundolo,et al.  Interaction Between Invariant NKT Cells and Myeloid-derived Suppressor Cells in Cancer Patients: Evidence and Therapeutic Opportunities , 2012, Journal of immunotherapy.

[2]  John M. Ashton,et al.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. , 2011, Blood.

[3]  R. Barker,et al.  Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function , 2011, Journal of leukocyte biology.

[4]  A. Rosato,et al.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. , 2011, Blood.

[5]  B. Dörken,et al.  A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants , 2011, European journal of haematology.

[6]  A. Puig-Kröger,et al.  Dendritic Cell-Specific ICAM-3–Grabbing Nonintegrin Expression on M2-Polarized and Tumor-Associated Macrophages Is Macrophage-CSF Dependent and Enhanced by Tumor-Derived IL-6 and IL-10 , 2011, The Journal of Immunology.

[7]  M. Merad,et al.  Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche , 2011, The Journal of experimental medicine.

[8]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Kuick,et al.  TGF-β-induced IRAK-M Expression in Tumor Associated Macrophages Regulates Lung Tumor Growth , 2010, Oncogene.

[10]  A. Mes-Masson,et al.  Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer , 2010, PloS one.

[11]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[12]  Matthew J. Craig,et al.  CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.

[13]  M. Lutz,et al.  Myeloid‐derived suppressor cell activation by combined LPS and IFN‐γ treatment impairs DC development , 2009, European journal of immunology.

[14]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[15]  E. Block,et al.  Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. , 2008, American journal of physiology. Cell physiology.

[16]  S. Albelda,et al.  Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response1 , 2007, The Journal of Immunology.

[17]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[18]  R. Hills,et al.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.

[19]  P. Musiani,et al.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Gabrilovich,et al.  Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species1 , 2004, The Journal of Immunology.

[21]  V. Bronte,et al.  L-arginine metabolism in myeloid cells controls T-lymphocyte functions. , 2003, Trends in immunology.

[22]  A. Visintin,et al.  Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism1 , 2002, The Journal of Immunology.

[23]  H. Prentice,et al.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia , 2001, Clinical and experimental immunology.

[24]  G. Mufti,et al.  Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways , 2001, The Journal of Immunology.

[25]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[26]  W. Grody,et al.  Comparative properties of arginases. , 1996, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[27]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[28]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[29]  W. Grody,et al.  Differential expression of the two human arginase genes in hyperargininemia. Enzymatic, pathologic, and molecular analysis. , 1989, The Journal of clinical investigation.

[30]  L. Sly,et al.  Generation and characterization of murine alternatively activated macrophages. , 2013, Methods in molecular biology.

[31]  P. Sinha,et al.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. , 2010, Cancer research.

[32]  Victor W H Ho,et al.  Derivation and characterization of murine alternatively activated (M2) macrophages. , 2009, Methods in molecular biology.

[33]  J. Buckley,et al.  A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.